Know Cancer

forgot password

Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)

Phase 1
18 Years
Open (Enrolling)
Glioblastoma Multiforme

Thank you

Trial Information

Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)


Recurrent glioma patients have very limited treatment options. A major cause of
gliomarelated morbidity and mortality is the extensive infiltrative and invasive nature of
glioma cells. Thus, inhibition of glioma invasion is a potentially promising strategy.

Work in the Neuro-Oncology Branch laboratory of Dr. Howard Fine has identified TrkA as an
important signaling receptor for mediating glioma cell invasion. Both genetic and
pharmacological inhibition of Trk potently inhibits glioma invasion and tumor progression in
vitro and in vivo. AZD7451 is a first in-class inhibitor of Trk.


To establish the maximally tolerated dose (MTD) of continuous twice a day AZD7451 dosing in
patients with recurrent glioblastoma not on enzyme-inducing anti-epileptic drugs (EIAED).

To generate pharmacokinetic data on continuous twice a day AZD7451 dosing.


Patients with histologically proven glioblastoma are eligible for this study. Patients
should have failed prior standard treatment with radiotherapy.


This study will accrue up to 60 evaluable patients. Cohorts of 3 to 6 patients will receive
continuous AZD7451 twice a day orally for 28 days. The MTD will be based on the tolerability
observed during the first 4 weeks of treatment only. Up to three patients may be enrolled
simultaneously at each dose level. The dose of AZD7451 can be progressively escalated if
only 0/3 or 1/6 patients experience a dose limiting toxicity at the prior dose level.

At the end of Cycle 1, patients may choose to continue to receive AZD7451 until disease
progression or until they experience unmanageable drug related toxicity, as long as they are
continuing to derive clinical benefit and do not fulfill any of the criteria for removal
from protocol therapy. Each cycle during this extension period will last 28 days.

Inclusion Criteria


- Patients with histologically proven malignant primary gliomas who have progressive
disease after radiotherapy will be eligible for this protocol.

- Patients must have an MRI scan performed within 14 days prior to registration and on
a fixed dose of steroids for at least 5 days. If the steroid dose is increased
between the date of imaging and registration a new baseline MRI is required.

- Patients having undergone recent resection of recurrent or progressive tumor will be
eligible as long as all of the following conditions apply:

1. Patients will be eligible four weeks after surgery if they have recovered from
the effects of surgery.

2. Residual disease following resection of recurrent tumor is not mandated for
eligibility into the study. To best assess the extent of residual disease
postoperatively, an MRI should be done:

- no later than 96 hours in the immediate post-operative period or

- at least 4 weeks post-operatively, and

- within 14 days of registration, and

- on a stable steroid dosage for at least 5 days.

If the 96 hour scan is more than 14 days before registration, the scan needs to be
repeated. If the steroid dose is increased between the date of imaging and registration, a
new baseline MRI is required on a stable steroid dosage for at least 5 days.

- Patients must have failed prior radiation therapy.

- Ability of subject or Legally Authorized Representative (LAR) (if the patient is
deemed by the treating physician to be cognitively impaired or questionably impaired
in such a way that the ability of the patient to give informed consent is
questionable) to understand and the willingness to sign a written informed consent
document indicating that they are aware of the investigational nature of this study.

- Patients must be greater than or equal to18 years old, and must have a life
expectancy > 8 weeks. Because no dosing or adverse event data are currently
available on the use of AZD7451 in patients < 18 years of age, children are excluded
from this study, but may be eligible for future pediatric trials.

- Patients must have a Karnofsky performance status of greater than or equal to 60

- Patients must be at least 4 weeks from radiation therapy. Additionally, patients must
be at least 6 weeks from nitrosoureas, 4 weeks from temozolomide, 3 weeks from
procarbazine, 2 weeks from vincristine and 2 weeks from last bevacizumab
administration. Patients must be at least 4 weeks from other cytotoxic therapies not
listed above and 2 weeks for non-cytotoxic agents (e.g., interferon, tamoxifen)
including investigative agents. With the exception of alopecia, all toxicities from
prior therapies should be resolved to CTCAE less than or equal to grade 1.

- Patients must have adequate bone marrow function (WBC greater than or equal to
3,000/microl, ANC greater than or equal to 1,500/mm(3), platelet count of greater
than or equal to 100,000/mm(3), and hemoglobin greater than or equal to 9 gm/dl),
adequate liver function (AST, ALT and alkaline phosphatase less than or equal to 2.5
times ULN and bilirubin less than or equal to 1.5 times ULN), and adequate renal
function (creatinine less than or equal to 1.5 times ULN and/or creatinine clearance
greater than or equal to 50 cc/min calculated by Cockcroft-Gault) before starting
therapy. Patients must also have serum potassium greater than or equal to 3.5 mmol/L,
magnesium, phosphate and calcium levels within normal levels; supplementation is
allowed. In cases where the serum calcium is below the normal range, 2 options would
be available: 1) the calcium adjusted for albumin is to be obtained and substituted
for the measured serum value. Exclusion is to then be based on the adjusted for
albumin values falling below the normal limit. 2) Determine the ionized calcium
levels. Exclusion is then to be based on whether these ionized calcium levels are out
of normal range despite supplementation. These tests must be performed within 14 days
prior to registration. Eligibility level for hemoglobin may be reached by

- Patients must either not be receiving steroids, or be on a stable dose of steroids
for at least five days prior to registration.

- The effects of AZD7451 on the developing human fetus are unknown. For this reason and
because AZD7451 is known to be teratogenic, women of child-bearing potential and men
must agree to use adequate contraception (hormonal or barrier method of birth
control; abstinence) prior to study entry and for the duration of study
participation. Should a woman become pregnant or suspect she is pregnant while she or
herpartner is participating in this study, the treating physician should be informed

- A 12 lead electrocardiogram (ECG) to be performed within 2 weeks of trial entry with
QTc less than or equal to 470 msec.

- Patients must have normal left ventricular ejection fraction (LVEF greater than or
equal to 55% or normal by NIH Clinical Center criteria).


- Patients who, in the view of the treating physician, have significant active hepatic,
renal, pulmonary or psychiatric diseases are ineligible.

- 2 Prior treatment with AZD7451.

- History of hypersensitivity to active metabolites or excipients of AZD7451.

- Clinically significant cardiovascular event (e.g. myocardial infarction, angina
pectoris, coronary artery bypass graft, angioplasty, vascular stent, superior vena
cava syndrome (SVC), New York Heart Association (NYHA, Appendix I) classification of
heart disease > 2 within 6 months before entry; or presence of cardiac disease that,
in the opinion of the investigator, increases the risk of ventricular arrhythmia.

- Hemorrhagic or ischemic stroke, including transient ischemic attacks and other
central nervous system bleeding in the preceding 6 months that were not related to
glioma surgery. History of prior intratumoral bleeding is not an exclusion criterion;
patients with history of prior intratumoral bleeding, however, need to undergo a
non-contrast head CT to exclude acute blood.

- Ventricular arrhythmias requiring continuous therapy or asymptomatic sustained
ventricular tachycardia within 12 months before study entry. Continuous or
intermittent atrial fibrillation requiring treatment. Patients with significant ECG
abnormalities such as complete left bundle block and third degree heart block are not

- QTc prolongation with other medications that required discontinuation of that

- Congenital long QT syndrome or 1st degree relative with unexplained sudden death
under 40 years of age.

- QTc with Bazett's correction that is unmeasurable, or > 470 msec on screening ECG.
(Note: If a subject has a QTc interval > 470 msec on screening ECG, the screen ECG
may be repeated twice (at least 24 hours apart). The average QTc from the three
screening ECGs must be less than or equal to 470 msec in order for the subject to be
eligible for the study. Patients who are receiving a drug that has a risk of QTc
prolongation excluded if QTc is greater than or equal to 460 msec.

- Any concurrent medication that may cause QTc prolongation or induce

Torsades de Pointes 1) Drugs listed in Appendix H, Table 2, that in the investigator's
opinion cannot be discontinued are allowed; however, must be monitored closely.

- Concomitant medications that are moderate or potent inducers or inhibitors of CYP3A4
are not permitted within the specified wash-out periods prior to or during treatment
with AZD7451

- Patients with a history of corneal disease such as corneal ulcers, corneal
dystrophies, keratoconus.

- Refractory nausea and vomiting or significant gastrointestinal impairment, as judged
by the investigator, that would significantly affect the absorption of AZD7451,
including the ability to swallow the oral solution.

- Patients known to have active hepatitis B or C (testing not required for entry on

- Other concomitant anti-cancer therapy except corticosteroids.

- Patients with a peripheral neuropathy CTCAE > 1 in the prior 4 weeks or active
muscle diseases (including dermatomyositis, polymyositis, inclusion body myositis,
muscular dystrophy and metabolic myopathy) or family history of myopathy. Patients
with pre-existing renal disease including glomerulonephritis, nephritic syndrome,
Fanconi syndrome or renal tubular acidosis.

- Evidence of active infection or active bleeding diatheses.

- Pregnant women are excluded from this study because AZD7451 is an agent with the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with AZD7451, breastfeeding should be discontinued if the mother is treated
with AZD7451. Female patients must have a negative pregnancy test prior to start of
dosing if of child-bearing potential or must have evidence of non-childbearing
potential by fulfilling one of the following criteria at screening:

- Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12
months following cessation of all exogenous hormonal treatments.

- Documentation of irreversible surgical sterilization by hysterectomy, bilateral
oophorectomy or bilateral salpingectomy but not tubal ligation.

- Patients known to have a malignancy (other than their malignant glioblastoma) that
has required treatment in the last 12 months and/or is expected to require treatment
in the next 12 months (except for non-melanoma skin cancer, carcinoma in situ in the
cervix or ductal carcinoma in situ).

- Major surgery within 4 weeks or incompletely healed surgical incision before starting

- Patients known to be HIV-positive (testing is not required for entry on study) and on
combination antiretroviral therapy are ineligible because of the potential for
pharmacokinetic interactions with AZD7451. In addition, these patients are at
increased risk of lethal infections when treated with marrow-suppressive therapy.
Appropriate studies will be undertaken in patients receiving combination
antiretroviral therapy when indicated.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To establish the maximum tolerated dose of AZD7451 on a continuous once daily schedule in patients with recurrent gliomas not on enzyme-inducing anti-epileptic drugs (EIAED).

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Teri N Kreisl, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

October 2011

Completion Date:

October 2014

Related Keywords:

  • Glioblastoma Multiforme
  • Brain
  • Angiogenesis
  • Radiotherapy
  • Malignant
  • Tumor
  • Glioma
  • Glioblastoma Multiforme
  • Brain Tumor
  • Glioblastoma



National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892